1. KalVista will host a webcast on September 11, 2025. 2. The webcast will provide operational updates and financial results. 3. KALV markets EKTERLY, the first oral HAE treatment. 4. Multiple regulatory applications are under review globally. 5. The company focuses on therapies for rare diseases.
The webcast may boost investor confidence by providing insights on growth and regulations, similar to past earnings calls that positively influenced stock prices.
The operational and financial updates could lead to significant adjustments in stock value based on performance, particularly in a company focusing on specialized therapies.
The imminent date of the webcast suggests an immediate effect on KALV's stock price, as investors often react quickly to news.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025.
The webcast can be accessed on the Investors section of the Company's website at Kalvista.com. A replay will be available for at least 30 days following the event.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250904776900/en/
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com